{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T10:59:22Z","timestamp":1786186762460,"version":"build-2736575974"},"reference-count":37,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Among individuals with the rare congenital bleeding disorder hemophilia A, the major challenge is inhibitor formation, which is associated with significant morbidity and cost. Yet, as the optimal approach to prevent and eradicate inhibitors is not known, we are at equipoise. Because classic trial design is not practical in a rare disease setting, we designed 2 48-week randomized trials comparing ELOCTATE and emicizumab to prevent and eradicate inhibitors. To achieve statistical efficiency, we incorporated historic data (Bayesian priors) on inhibitor formation to allow preferential randomization to emicizumab, piecewise exponential survival models to determine mean and 95% confidence interval for inhibitor formation in each arm, and simulations to determine the best model design to optimize power. To achieve administrative efficiency, the trials will be performed with the same sites, staff, visit frequency, blood sampling, laboratories, and laboratory assays, with streamlined enrollment so patients developing inhibitors in the first trial may be enrolled on the second trial. The primary end point is the probability of inhibitor formation or inhibitor eradication, respectively. The design indicates early stopping rules for overwhelming evidence of superiority of the emicizumab arms. Simulations indicate that, with 66 subjects, the Prevention Trial will have 84% power to detect noninferiority of emicizumab to ELOCTATE with a margin of 10% if emicizumab is truly 10% superior to ELOCTATE; with 90 subjects, the Eradication Trial will have 80% power to detect 15% superiority of ELOCTATE immune tolerance induction with vs without emicizumab. Thus, a platform design provides statistical and administrative efficiency to conduct INHIBIT trials.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002789","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T16:37:52Z","timestamp":1604680672000},"page":"5433-5441","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-9033","authenticated-orcid":false,"given":"Marnie","family":"Bertolet","sequence":"first","affiliation":[{"name":"Department of Epidemiology,"},{"name":"Department of Biostatistics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2030-7873","authenticated-orcid":false,"given":"Maria M.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Department of Epidemiology,"},{"name":"Department of Biostatistics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA; and"},{"name":"Hemophilia Center of Western PA, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"issue":"6","key":"2020110611374283300_B1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2020110611374283300_B2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1365-2516.2009.02058.x","article-title":"Risk factors for inhibitor formation in haemophilia: a prevalent case-control study","volume":"15","author":"Ragni","year":"2009","journal-title":"Haemophilia"},{"issue":"20","key":"2020110611374283300_B3","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"van den Berg","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2020110611374283300_B4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2516.2001.00484.x","article-title":"Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia","volume":"7","author":"Soucie","year":"2001","journal-title":"Haemophilia"},{"key":"2020110611374283300_B5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0609.1998.tb01107.x","article-title":"Pharmaco-economic aspects of inhibitor treatment","volume":"63","author":"Goudemand","year":"1998","journal-title":"Eur J Haematol Suppl"},{"issue":"5","key":"2020110611374283300_B6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"2020110611374283300_B7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/hae.13717","article-title":"The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors","volume":"25","author":"Ragni","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"2020110611374283300_B8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jth.12076","article-title":"Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein","volume":"11","author":"Peters","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2020110611374283300_B9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cellimm.2015.12.008","article-title":"Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice","volume":"301","author":"Krishnamoorthy","year":"2016","journal-title":"Cell Immunol"},{"issue":"13","key":"2020110611374283300_B10","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2020110611374283300_B11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2020110611374283300_B12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"9","key":"2020110611374283300_B13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2020110611374283300_B14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"2020110611374283300_B15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020110611374283300_B16","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"2020110611374283300_B17","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1111\/hae.13032","article-title":"Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein","volume":"22","author":"Ragni","year":"2016","journal-title":"Haemophilia"},{"key":"2020110611374283300_B18","first-page":"32","article-title":"Incidence of inhibitors in previously untreated patients with severe haemophilia A treated with rFVIIIFc: the PUPs A-LONG study [abstract]","volume":"25","author":"K\u00f6nigs","year":"2019","journal-title":"Haemophilia"},{"issue":"6","key":"2020110611374283300_B19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/17474086.2014.963550","article-title":"Design of the INHIBIT trial: preventing inhibitors by avoiding \u201cdanger,\u201d prolonging half-life and promoting tolerance","volume":"7","author":"Ragni","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2020110611374283300_B20","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1111\/hae.13064","article-title":"Extended half-life factor VIII for immune tolerance induction in hemophilia","volume":"22","author":"Malec","year":"2016","journal-title":"Haemophilia"},{"issue":"2","key":"2020110611374283300_B21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.13413","article-title":"Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis","volume":"24","author":"Carcao","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"2020110611374283300_B22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"Batsuli","year":"2019","journal-title":"Haemophilia"},{"issue":"6","key":"2020110611374283300_B23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2020110611374283300_B24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/hae.12830","article-title":"Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction","volume":"22","author":"Ragni","year":"2016","journal-title":"Haemophilia"},{"issue":"11","key":"2020110611374283300_B25","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2020110611374283300_B26","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1111\/j.1365-2516.2011.02646.x","article-title":"Challenges of rare disease research: limited patients and competing priorities","volume":"18","author":"Ragni","year":"2012","journal-title":"Haemophilia"},{"issue":"4","key":"2020110611374283300_B27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1365-2516.2009.02031.x","article-title":"Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?","volume":"15","author":"Iorio","year":"2009","journal-title":"Haemophilia"},{"issue":"10","key":"2020110611374283300_B28","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jclinepi.2010.12.019","article-title":"A framework for applying unfamiliar trial designs in studies of rare diseases","volume":"64","author":"Gupta","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2020110611374283300_B29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/hae.12415","article-title":"Joint WFH-ISTH session: issues in clinical trial design","volume":"20","author":"Peyvandi","year":"2014","journal-title":"Haemophilia"},{"issue":"1","key":"2020110611374283300_B30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharm Stat"},{"issue":"3","key":"2020110611374283300_B31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","article-title":"Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative","volume":"51","author":"Bogaerts","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"2020110611374283300_B32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.285","article-title":"Emerging innovations in clinical trial design","volume":"99","author":"Berry","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2020110611374283300_B33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/JBM.S103087","article-title":"Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study","volume":"7","author":"Cheng","year":"2016","journal-title":"J Blood Med"},{"issue":"2","key":"2020110611374283300_B34","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1470-2045(15)00396-4","article-title":"Research methods to change clinical practice for patients with rare cancers","volume":"17","author":"Billingham","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020110611374283300_B35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"},{"issue":"1","key":"2020110611374283300_B36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/2531910","article-title":"Sample sizes based on the log-rank statistic in complex clinical trials","volume":"44","author":"Lakatos","year":"1988","journal-title":"Biometrics"},{"issue":"14","key":"2020110611374283300_B37","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/sim.1193","article-title":"Designing complex group sequential survival trials","volume":"21","author":"Lakatos","year":"2002","journal-title":"Stat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/21\/5433\/1789126\/advancesadv2020002789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/21\/5433\/1789126\/advancesadv2020002789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T01:26:18Z","timestamp":1723857978000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/21\/5433\/474083\/The-design-of-a-Bayesian-platform-trial-to-prevent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":37,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002789","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]}}}